Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65(11):1861-1870.

Publication Type:

Journal Article

Authors:

T M Welzel; Petersen, J.; Herzer, K.; et, al

Source:

Gut, Volume 65, Issue 11, p.1861-1870 (2016)

Cited On:

Patients With Decompensated Cirrhosis

External Third-party Web Link:

https://www.ncbi.nlm.nih.gov/pubmed/27605539

Export Citation:

RIS Format

Top